KPC Pharmaceuticals, Inc. Class A

KPC Pharmaceuticals, Inc. Class A

SSSE:600422
8.47
CNY
0.00
(0.00%)
-0.36EPS
6.14BMarket Cap
Mar 19Next Earn

Total Valuation

CNY

As of September 30, 2026, KPC Pharmaceuticals, Inc. Class A carries a market capitalization of 6.14B, placing it among publicly traded companies globally. Its enterprise value stands at 7.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.14B
Enterprise Value7.83B

Important Dates

KPC Pharmaceuticals, Inc. Class A's next confirmed earnings release is scheduled for March 19, 2027.

Earnings Date3/19/2027

Share Statistics

As of September 30, 2026, KPC Pharmaceuticals, Inc. Class A has 756.98M shares outstanding.

Shares Outstanding756.98M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 1.35, and the price-to-book ratio stands at 1.26.

PS Ratio1.35
PB Ratio1.26
P/TBV Ratio2.25

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 1.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.83B versus a market cap of 6.14B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.72

Financial Position

As of September 30, 2026, KPC Pharmaceuticals, Inc. Class A maintains a current ratio of 2.11, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.94, indicating elevated leverage, while an interest coverage ratio of -9.94 demonstrates limited ability to service its debt obligations.

Current Ratio2.11
Quick Ratio0.44
Debt / Equity22.94
Debt / EBITDA-4.37
Interest Coverage-9.94

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 896,369.66 in revenue per employee across its workforce of 5,072.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee896,369.66
Employee Count5,072.00

Taxes

CNY

Over the twelve months ended September 30, 2026, KPC Pharmaceuticals, Inc. Class A recorded an income tax benefit of -50.26M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -318.06M and -285.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-50.26M

Stock Price Statistics

CNY

As of the close on November 17, 2026, KPC Pharmaceuticals, Inc. Class A's stock has declined approximately 37.95% over the past 52 weeks. The 50-day moving average sits at 8.47, while the 200-day moving average is 9.68.

52-Week Price Change-37.95%
50-Day Moving Average8.47
200-Day Moving Average9.68

Income Statement

CNY

Over the twelve months ended September 30, 2026, KPC Pharmaceuticals, Inc. Class A generated 4.55B in revenue and converted that into -285.36M in net income, yielding earnings per share of -0.36. EBITDA reached -338.15M, while operating income came in at -173.99M.

Revenue4.55B
Gross Profit1.25B
Operating Income-173.99M
Pretax Income-318.06M
Net Income-285.36M
EBITDA-338.15M
EBIT-338.15M
Earnings Per Share (EPS)-0.36

Balance Sheet

CNY

As of September 30, 2026, KPC Pharmaceuticals, Inc. Class A holds 1.37B in cash and equivalents against 1.48B in total debt, resulting in a net debt position of 664.60M. Total book value stands at 4.86B, with working capital of 3.45B providing operational flexibility.

Cash & Cash Equivalents1.37B
Total Debt1.48B
Net Debt664.60M
Equity (Book Value)4.86B
Book Value Per Share6.42
Working Capital3.45B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-126.39M

Margins

Over the twelve months ended September 30, 2026, KPC Pharmaceuticals, Inc. Class A posted a gross margin of 27.46, reflecting its pricing power and cost economics. The operating margin of -3.83 and net profit margin of -6.28 provide insight into operational efficiency.

Gross Margin27.46
Operating Margin-3.83
Pretax Margin-7.00
Profit Margin-6.28
EBITDA Margin-7.44

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, KPC Pharmaceuticals, Inc. Class A paid dividends of 0.24 per share. The dividend payout ratio of -73.21 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 16.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KPC Pharmaceuticals, Inc. Class A shareholders.

Dividend Per Share0.24
Payout Ratio-73.21
Shareholder Yield16.00

Stock Splits

KPC Pharmaceuticals, Inc. Class A's most recent stock split took place on May 9, 2016 with a 1:2 split ratio.

Last Split Date5/9/2016
Split Ratio1:2

Scores

As of September 30, 2026, KPC Pharmaceuticals, Inc. Class A has an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.41